Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight
The generalized anxiety disorder market across the 7MM is expected to grow significantly during the forecast period (2026-2036). Key drivers include the increasing prevalence of the disease, advancements in diagnostic tools, heightened patient awareness, growing investments in innovative therapies such as DT120 ODT (LSD D-Tartrate) (Definium Therapeutics), Ulotaront (SEP-363856) (Sumitomo Pharma/Otsuka), HLP004 (Helus Pharma), ITI-1284 (Intra-Cellular Therapies, Inc.), ABBV-932 (AbbVie), and others, and supportive regulatory frameworks, reports DelveInsight.
LAS VEGAS, June 4, 2026 /PRNewswire/ -- Recently published Generalized Anxiety Disorder Market Insights report includes a comprehensive understanding of current treatment practices, generalized anxiety disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Generalized Anxiety Disorder Market Summary
Discover why is the GAD market growing and what are key drivers @ https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market
Key Factors Driving the Growth of the Generalized Anxiety Disorder Market
Ramandeep Singh, Senior Consultant of Forecasting and Analytics at DelveInsight, said that GAD treatment still faces challenges, as many current therapies have safety concerns and a slow onset of action. Older medication classes often come with troublesome side effects, highlighting the need for safer and more effective options. Encouragingly, new therapies such as DT120 ODT (LSD D-Tartrate), Ulotaront (SEP-363856), HLP004, ITI-1284, ABBV-932, and others in development offer hope for significant advancements in managing GAD.
Generalized Anxiety Disorder Market Analysis
Generalized Anxiety Disorder Competitive Landscape
Some of the GAD drugs under development include DT120 ODT (LSD D-Tartrate) (Definium Therapeutics), Ulotaront (SEP-363856) (Sumitomo Pharma/Otsuka), HLP004 (Helus Pharma), ITI-1284 (Intra-Cellular Therapies, Inc.), ABBV-932 (AbbVie), and others.
Definium Therapeutics' DT120 orally disintegrating tablets are an optimized formulation of lysergide D-tartrate (LSD) developed by Definium Therapeutics. This version is engineered to improve bioavailability, allow fast uptake, and reduce gastrointestinal effects through Catalent's Zydis fast-dissolve platform. DT120 ODT functions as a partial serotonin-receptor agonist, promoting greater neural connectivity—an effect that may help reduce GAD symptoms by targeting underlying network dysregulation.
Sumitomo Pharma/Otsuka's Ulotaront is an investigational TAAR1 and 5-HT1A receptor agonist being developed as a new oral therapy for GAD. By engaging these receptors, it seeks to influence neurotransmission in a manner distinct from standard anxiolytics, potentially introducing a novel therapeutic pathway. It is currently in Phase II/III trials in the U.S. and Japan to assess both effectiveness and safety for GAD treatment.
AbbVie's ABBV-932 is a selective dopamine D3-receptor modulator under clinical investigation as a standalone therapy for bipolar depression and as an add-on treatment for generalized anxiety disorder. It is being developed collaboratively with Gedeon Richter.
The anticipated launch of these emerging therapies are poised to transform the generalized anxiety disorder market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the generalized anxiety disorder market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about emerging therapies and drug pipeline impact @ Generalized Anxiety Disorder Drugs
Recent Developments in the Generalized Anxiety Disorder Market
What is Generalized Anxiety Disorder?
Generalized anxiety disorder (GAD) is a mental health condition characterized by persistent, excessive worry about everyday situations, even when there is little or no reason for concern. People with GAD often find it difficult to control their anxiety and may experience symptoms such as restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and trouble sleeping. Unlike temporary stress that comes and goes, the worry in GAD is ongoing, affects multiple areas of life, and can interfere with daily functioning. It's a manageable condition, and many people find relief through therapy, lifestyle adjustments, and, when appropriate, medication under professional guidance.
Generalized Anxiety Disorder Epidemiology Segmentation
The generalized anxiety disorder epidemiology section provides insights into the historical and current generalized anxiety disorder patient pool and forecasted trends for the leading markets. According to the secondary analysis, in the UK, GAD is more prevalent in women than men, and around two-thirds of those diagnosed with GAD are female.
The generalized anxiety disorder treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Generalized Anxiety Disorder Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Generalized Anxiety Disorder Epidemiology Segmentation
Total Prevalent Cases of GAD, Total Diagnosed Prevalent Cases of GAD, Gender-specific Diagnosed Prevalent Cases of GAD, Age-specific Diagnosed Prevalent Cases of GAD, Severity-specific Diagnosed Prevalent Cases of GAD, and Total Treated Cases of GAD
Key Generalized Anxiety Disorder Companies
Definium Therapeutics, Sumitomo Pharma, Otsuka, Helus Pharma, Intra-Cellular Therapies, Inc., AbbVie, and others
Key Generalized Anxiety Disorder Therapies
DT120 ODT (LSD D-Tartrate), Ulotaront (SEP-363856), HLP004, ITI-1284, ABBV-932, and others
Scope of the Generalized Anxiety Disorder Market Report
Download the report to understand prevalence of GAD and impact on market demand @ Generalized Anxiety Disorder Market Analysis
Table of Contents
1
Generalized Anxiety Disorder Market Key Insights
2
Generalized Anxiety Disorder Market Report Introduction
3
Generalized Anxiety Disorder Market Overview at a Glance
3.1
Market Share (%) Distribution of GAD by Therapies in 2022
3.2
Market Share (%) Distribution of GAD by Therapies in 2036
4
Methodology of Epidemiology and Market
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and Symptoms
7.3
Causes
7.4
Related Conditions
7.5
Etiology
7.6
Risk Factors
7.7
Pathophysiology
7.8
Complications
7.9
Diagnosis
8
Epidemiology and Patient Population
8.1.
Key Findings
8.2.
Methodology of Epidemiology
8.3.
Assumptions and Rationale: the 7MM
8.3.1.
The US
8.3.2.
EU4 and the UK
8.3.3.
Japan
8.3
Total Diagnosed Prevalent Cases of GAD in the 7MM
8.4
The US
8.4.1
Total Prevalent Cases of GAD in the US
8.4.2
Total Diagnosed Prevalent Cases of GAD in the US
8.4.3
Age-specific Diagnosed Prevalent Cases of GAD in the US
8.4.4
Gender-specific Diagnosed Prevalent Cases of GAD in the US
8.4.5
Severity-specific Diagnosed Prevalent Cases of GAD in the US
8.4.6
Treated Cases of GAD in the US
8.5
EU4 and the UK
8.6
Japan
9
Generalized Anxiety Disorder Patient Journey
10
Emerging Generalized Anxiety Disorder Drugs
10.1
Key Cross Competition
10.2
DT120 ODT (LSD D-Tartrate): Definium Therapeutics
10.2.1
Product Description
10.2.2
Other Developmental Activities
10.2.3
Clinical Trials Information
10.2.4
Safety and Efficacy
10.2.5
Analysts' View
10.3
Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka
List to be continued in the final report…
11
GAD: Market Analysis
11.1
Key Findings
11.2
Key Generalized Anxiety Disorder Market Forecast Assumptions
11.3
Generalized Anxiety Disorder Market Outlook
11.4
Attribute Analysis
11.5
Total Market Size of GAD in the 7MM
11.6
Total Market Size of GAD by Therapies in the 7MM
11.7
Market Size of GAD in the US
11.7.1
Total market size of GAD
11.7.2
The market size of GAD by Therapies
11.8
Market Size of GAD in EU4 and the UK
11.9
Market Size of GAD in Japan
12
Key Opinion Leaders' Views on GAD
13
Generalized Anxiety Disorder Market Unmet Needs
14
Generalized Anxiety Disorder Market SWOT Analysis
15
GAD Market Access and Reimbursement
15.1
The United States
15.2
In EU4 and the UK
15.3
Japan
16
Bibliography
17
Acronyms and Abbreviations
18
Generalized Anxiety Disorder Market Report Methodology
Related Reports
Generalized Anxiety Disorder Clinical Trial Analysis
Generalized Anxiety Disorder Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GAD companies, including Fabre-Kramer Pharmaceuticals, Inc., Luye Pharma Group Ltd., Otsuka Pharmaceutical Co., Ltd., Engrail Therapeutics, Intra-Cellular Therapies Inc., Incannex, AbbVie, GABA Therapeutics, Inc., and others.
Major Depressive Disorder Market
Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MDD companies including Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Luye Pharma, Relmada Therapeutics, BioLite Inc., VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Neurocrine Biosciences, Arrivo Bioventures, Sirstei Pharmaceuticals, Alto Neuroscience, Chase Therapeutics, Neumora Therapeutics, Inc., BlackThorn Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Fabre-Kramer Pharmaceuticals, Novartis, and others.
Social Anxiety Disorder Market
Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key social anxiety disorder companies including Mochida Pharmaceutical, Lundbeck, Vistagen Therapeutics, Bionomics, EmpowerPharm, and others.
Acute Social Anxiety Disorder Market
Acute Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute social anxiety disorder companies including Mochida Pharmaceutical, Lundbeck, Vistagen Therapeutics, Bionomics, EmpowerPharm, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP